Pirfenidone CAS 53179-13-8 Purity ≥99.0% IPF

Chemical Name: Pirfenidone  CAS: 53179-13-8 Purity: ≥99.0% Appearance: White to Light Yellow Crystalline Powder High Quality, Commercial Production For the treatment of Idiopathic Pulmonary Fibrosis (IPF) E-Mail: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Supply With High Purity, Commercial Production  Chemical Name: Pirfenidone  CAS: 53179-13-8
Item Specifications
Appearance White to Light Yellow Crystalline Powder
Identification IR
Purity ≥99.0%
Loss on Drying ≤0.50%
Sulfated Ash ≤0.20%
Single Impurity ≤0.50%
Total Impurities ≤1.0%
Heavy Metals ≤20ppm
Test Standard Enterprise Standard
Usage API, Idiopathic Pulmonary Fibrosis (IPF)

Description:

Specifications:

Package & Storage:

Chemical Name Pirfenidone
Synonyms Perfenidone; 5-Methyl-1-Phenylpyridine-2(1H)-one; PFD; S-7701; AMR-69
CAS Number 53179-13-8
CAT Number RF-API108
Stock Status In Stock 
Molecular Formula C12H11NO
Molecular Weight 185.22
Melting Point  96.0 to 97.0℃
Solubility  Soluble in DMSO
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

Pirfenidone (CAS: 53179-13-8) is in a group of medicines called antifibrotic agents. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It affects your body’s immune system and reduces the amount of fibrosis (scarring) in the lungs. Pirfenidone is one of two medicines that are approved in Canada to treat Idiopathic Pulmonary Fibrosis (IPF). Pirfenidone is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. It was first approved in Japan for the treatment of patients with idiopathic pulmonary fibrosis after clinical trials, under the trade name of Pirespa by Shionogi, in 2008. It was approved for use in the European Union in 2011, in Canada in 2012, and in the United States in October 2014.  

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours